1-4 of 4
Susan Saidman, PhD
Close
Sort by
Journal Articles

Long Term Follow-up of Recipients of Combined HLA-Matched Nonmyeloablative Bone Marrow and Kidney Transplantation for Multiple Myeloma with End-Stage Renal Disease.

Thomas R Spitzer, MD, Megan Sykes, MD, Nina Tolkoff Rubin, MD, Tatsuo Kawai, MD, Steven L McAfee, MD, Bimalangshu Dey, MD, PhD, Karen Ballen, MD, Francis Delmonico, MD, Susan Saidman, PhD, David H Sachs, M.D., Benedict Cosimi, MD
Journal: Blood
Blood (2009) 114 (22): 3368.
https://doi.org/10.1182/blood.V114.22.3368.3368
Published: 2009
Journal Articles

Non-Myeloablative T-Cell Depleted (TCD) Haploidentical Hematopoietic Cell Transplantation (HCT) Followed by Donor Leukocyte Infusion(s) for Hematologic Malignancies: The MGH Experience.

Bimalangshu R. Dey, MD, PhD, Andrew J. Yee, MD, Steven McAfee, MD, Christine Dube, Karen Ballen, MD, Eyal Attar, MD, Christine Colby, Susan Saidman, PhD, Karen Malikowski, Frederic Preffer, PhD, Megan Sykes, MD, Thomas R. Spitzer, MD
Journal: Blood
Blood (2007) 110 (11): 5088.
https://doi.org/10.1182/blood.V110.11.5088.5088
Published: 2007
Journal Articles

Outcomes of Patients with Engraftment Syndrome (ES) Following Nonmyeloablative Hematopoietic Stem Cell Transplant (SCT) for Hematologic Malignancy(HM).

Erica Linden, MD, Steven L. McAfee, MD, Bimalangshu R. Dey, MD, Karen Ballen, MD, Susan Saidman, PhD, Christine Colby, PharmD, Megan Sykes, MD, Thomas R. Spitzer, MD
Journal: Blood
Blood (2005) 106 (11): 3661.
https://doi.org/10.1182/blood.V106.11.3661.3661
Published: 2005
Journal Articles

In Vivo and Ex Vivo T-Cell Depleted (TCD) NonmyeloablativeHaploidentical Stem Cell Transplantation (NSCT) for Hematologic Malignancy (HM).

Thomas R. Spitzer, MD, Steven L. McAfee, MD, Dey R. Bimalangshu, MD, Karen Ballen, MD, Eyal Attar, MD, Christine Colby, PharmD, Fred Preffer, PhD, Susan Saidman, PhD, Juanita Shaffer, David H. Sachs, MD, Megan Sykes, MD
Journal: Blood
Blood (2005) 106 (11): 5431.
https://doi.org/10.1182/blood.V106.11.5431.5431
Published: 2005